5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Venus Remedies Ltd.

•
venusremedies.com / www.vmrcindia.comBSE: 526953NSE: VENUSREM
Market Cap₹ 2,182 Cr.
Current Price
High / Low₹ 2,044 / 424
Stock P/E18.8
Book Value₹ 514
Price to Book1.66
Dividend Yield0.61 %
ROCE21.9 %
ROE16.8 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 139.3% YoY, showing strong momentum
  • Company has consistently been profitable over the last 5 years
  • Operating margins have improved to 19.1% from 12.7%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.58x)

CONS

  • Valuation is stretched - P/E of 18.8 is well above its own 5-year median (10.7)
  • Company has delivered a poor sales growth of 7.0% over past five years
  • Though reporting repeated profits, the company pays out little dividend (13.0%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.VENUSREM1632.2518.782181.830.6122.97139.27178.8635.6021.8819.12
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
95168143195109170177198132193180259179
8515013117697163158166122162143196151
Operating Profit1018121911818321031386327
OPM %10.93%10.58%8.39%9.98%10.37%4.44%10.21%16.03%7.66%16.06%20.81%24.45%15.33%
23242812492353
Interest0000000000000
Depreciation8676665566777
Profit before Tax5148177925311326336230
Tax %76.63%30.68%11.95%39.84%82.19%61.30%21.22%32.35%23.81%24.01%23.57%22.92%23.54%
Net Profit00001420211020264723
0.887.445.137.860.922.6314.6615.717.1815.0619.1435.5317.18

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
400372322339548600556601653770811
349333289299494538495542584622652
Operating Profit513933415462606069147159
OPM %12.68%10.60%10.10%12.03%9.81%10.35%10.81%9.91%10.50%19.14%19.64%
42-3-44381012261312
Interest3636251313000000
Depreciation4034343235343226232626
Profit before Tax-22-28-30-84936384572134152
Tax %21.06%-11.48%3.87%-24.44%-27.21%-11.85%29.96%36.18%36.91%23.38%23.38%
Net Profit-17-31-29-106241272845103116
EPS0.000.000.000.0050.0430.8619.8821.3133.9076.90—
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%13.00%—

COMPOUNDED SALES GROWTH

10 Years:
6%
5 Years:
7%
3 Years:
11%

COMPOUNDED PROFIT GROWTH

10 Years:
51%
5 Years:
11%
3 Years:
57%

STOCK PRICE CAGR

10 Years:
33%
5 Years:
27%
3 Years:
91%
1 Year:
257%

RETURN ON EQUITY

10 Years:
4%
5 Years:
9%
3 Years:
10%
Last Year:
17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 7

₹ 1

Rs.10.0000 per share(100%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital12121212121313131313
376350320311374427447474548650
28225922915851434241211
Trade Payables302936377150515392113
65100135126474648456165
Total Liabilities765751733644556579601627716854
406389364289262241216219229232
Capital Work in Progress66656525252526212651
000000201984238
141138143141120126120122100129
000000080112103
Cash & Bank4432315054688030
148155158187118137164988371
Total Assets765751733644556579601627716854

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
5931456310841373786156
Cash from Investing-18-11-11-556-17-51-7-76-182
Cash from Financing-44-39-35-73-162-9-1-1-1-3
-4-20-1-02615-15299-29

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
41.7641.7641.7641.7641.7641.7641.7641.7641.76
1.061.181.111.342.251.862.252.802.92
0.000.000.000.000.110.751.031.200.89
Government0.000.000.000.000.000.000.000.000.00
57.1857.0657.1356.9055.8955.6354.9654.2454.43

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Copy of Newspaper Publication

2026-09-10 - Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-09
Copy of Newspaper Publication

2026-09-09 - Venus Remedies Limited has informed the Exchange about newspaper publication of notice to physical shareholders for transfer of physical shares as per SEBI circular.

2026-09-07
Updates

2026-09-07 - Venus Remedies Limited has informed the Exchange regarding Social Media Post on awareness on transfer of physical shares ''.

2026-08-21
Shareholders meeting

2026-08-21 - Voting Results and Scrutinizer's report. Earlier submitted file was not machine readable.

2026-08-21
Shareholders meeting

2026-08-21 - Venus Remedies Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 20, 2026. Further, the company has informed the Exchange regarding voting results.

2026-08-21
Amendment to AOA/MOA

2026-08-21 - Venus Remedies Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.

2026-08-20
Appointment

2026-08-20 - Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. Gurminder Singh Bedi as Non- Executive Independent Director of the company w.e.f. May 26, 2026.

2026-08-20
Appointment

2026-08-20 - Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. (Mrs.) Manu Chaudhary as Joint Managing Director of the company w.e.f. October 01, 2026.

2026-08-20
Appointment

2026-08-20 - Venus Remedies Limited has informed the Exchange regarding Appointment of Dr. (Mrs.) Savita Gupta as Non- Executive Independent Director of the company w.e.f. December 30, 2026.

News

Recent coverage and analyst commentary for VENUSREM

Loading news…

🤖

AI Stock Analyst

Venus Remedies Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login